RTI Surgical (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that its C-Plus™ Peek* IBF System is now indicated for use with allograft, including its proprietary map3 ® cellular allogeneic bone graft.

"This indication is important news because it now gives surgeons options that they didn't have before," noted Brian Hutchison, RTI president and chief executive officer. "Previously, the C-Plus Peek IBF System was indicated for use with only autograft, but now surgeons have more options and can tailor treatment to each individual patient's needs."

The map3 cellular allogeneic bone graft supports the body's innate healing mechanisms and provides the scaffold and signals to support bone growth. The implant contains the three essential elements of bone formation (cortical cancellous bone chips supply an osteoconductive scaffold, demineralized bone matrix demonstrates verified osteoinductive potential and MAPC ®-class cells, a specific type of stem cell provides osteogenic and angiogenic signals to support the bone healing process). The C-Plus Peek IBF System is a PEEK interbody fusion system that offers multiple options and features designed to provide stability and anatomic restoration, facilitating fusion, when used with autogenous bone graft, and/or allogenic bone graft comprised of cancellous, cortical, and/or corticocancellous bone graft, in anterior cervical discectomy and fusion (ACDF) surgery.

"We are pleased to have received this indication for the C-Plus system, which expands our product portfolio that can be used with one of our key product innovations, map3 cellular allogeneic bone graft," Hutchison said. "We can now offer surgeons an all-inclusive RTI portfolio with C-Plus implants, map3 allograft and the Aspect ® Anterior Cervical Plate (ACP) System, proving once more our commitment to providing surgeons with integrated offerings to help their patients."

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI's implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.

*PEEK-OPTIMA ® from Invibio ® Biomaterial Solutions

® indicates U.S. trademark registration. All trademarks and/or images are the property of their respective owners or holders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005644/en/

Copyright Business Wire 2010